Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.88 USD | +1.67% |
|
-0.54% | -14.51% |
14/06 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating | MT |
14/06 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.51% | 369.99Cr | |
+16.61% | 12TCr | |
+17.75% | 11TCr | |
+17.23% | 2.59TCr | |
-24.11% | 1.93TCr | |
-18.56% | 1.62TCr | |
-18.47% | 1.56TCr | |
-47.75% | 1.46TCr | |
+57.35% | 1.43TCr | |
+5.62% | 1.4TCr |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-13-2020 through Jan-16-2020